SecBot SecBot
SC 13G ·Filed Nov 6, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed10d 15h ago SEC0001897612-26-000699
Passive investor 5%+ stake
Actionable Insight • Neutral

T. Rowe Price's 8.2% passive stake adds a major institutional holder to the base. Monitor future 13G amendments for any stake changes and watch for any 13D conversion if the holder's intent shifts, though the filing explicitly disclaims activist purpose.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$39.17
T+0 close · Nov 6, 2026 · via day close
Latest settled
+3.34%
T+5 · $40.48
Vs SPY
+0.75%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $39.17entry
  2. T+1 · 8d ago +3.27%α +0.90% · $40.45
  3. T+5 · 4d ago +3.34%α +0.75% · $40.48
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

T. Rowe Price Investment Management filed a Schedule 13G disclosing a 8.2% passive stake in Xenon Pharmaceuticals as of September 30, 2026, representing 7,905,757 shares. This is a new 13G filing by T. Rowe Price, indicating a significant passive institutional position in the biotech company.

Key Financial Metrics

Stake
8.2%
Investor
T. Rowe Price Investment Management, Inc.
Investor Type
mutual fund

Key Facts

  • T. Rowe Price Investment Management disclosed beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals common stock as of September 30, 2026
  • The stake represents 8.2% of outstanding shares
  • The filing is a new Schedule 13G, not an amendment
  • T. Rowe Price certifies passive intent under Rule 13d-1(b)
  • Sole voting power is held over 7,558,551 shares; sole dispositive power over 7,905,757 shares

Financial Impact

8.2% stake valued at approximately $312 million based on $3.8B market cap

ownership concentration

Risk Factors

  • No stated intent to influence management or strategy
  • Passive filing; stake could be reduced without public notice until next threshold

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001897612-26-000699
Document: 0001897612-26-000699-index.html0001897612-26-000699
Document: 0001897612-26-000699.txt0001897612-26-000699

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Viewing Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026